Background: We aimed to investigate the results of anti-tumor necrosis factor (TNF) therapy in patients with a previous history of tuberculosis (TB). Methods: A total of 101 patients with a previous history of TB receiving TNF antagonists between December 2004 and September 2012 at the Asan Medical Center in South Korea were retrospectively analyzed. Results: The mean age of the 101 subjects was 40.4 AE 16.0 years and 51 patients (50.5%) were male. The underlying immune-mediated inflammatory diseases (IMIDs) were Crohn's disease in 55 (54.5%), rheumatoid arthritis in 27 (26.7%), and ankylosing spondylitis in 13 (12.9%) patients. Chest radiography findings were suggestive of previous TB lesions in 33 (32.7%) patients. The rates of positivity in the tuberculin skin test and interferon-gamma release assay were 21.8% (22/101) and 44.6% (45/101), respectively. Latent TB infection (LTBI) treatment was initiated in 11 subjects (10.9%) based on previous inappropriate anti-TB treatments (n Z 10) or recent TB contact history (n Z 1), irrespective of the LTBI test results. The median follow-up duration
Introduction
Tumor necrosis factor (TNF) antagonists are increasingly used to treat patients with immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis (UC) [1] . Because TNF is an essential component of host defenses against Mycobacterium tuberculosis, patients treated with TNF antagonists show an increased incidence of tuberculosis (TB), mostly due to the reactivation of latent TB infection (LTBI) [2] . Reactivation of LTBI can be considerably reduced by screening patients with IMIDs for LTBI before initiating treatment with TNF antagonists, and by promptly initiating appropriate prophylactic therapy if needed [1,3e5] .
Current diagnostic tests for LTBI, including tuberculin skin tests (TST) and/or interferon-gamma release assays (IGRAs), are not recommended for patients with a previous history of TB because these patients are likely to be positive, even in the absence of current infection, and the results of these tests do not affect the decision to treat LTBI. Accordingly, the British Thoracic Society (BTS) has recommended that patients with a history of TB who previously received adequate treatment can begin TNF antagonists without LTBI treatment [6] . However, patients in a TBprevalent country can become reinfected after completion of a previous treatment. In addition, the adequacy of previous TB treatment may be unclear if patients have received treatment many years earlier. Clinicians are also concerned about prescribing TNF antagonists in the absence of LTBI treatment when chest X-ray (CXR) shows lesions indicative of TB sequalae lesions, even if previous anti-TB treatments were adequate. To date, however, few studies have analyzed the use of TNF antagonists in patients with a previous history of TB.
This study was designed to investigate 1) the percentage of patients receiving LTBI treatment before beginning anti-TNF treatment, 2) factors influencing the decision to initiate LTBI treatment, and 3) the incidence of TB during anti-TNF therapy in patients with a previous TB history in South Korea, a country with an intermediate TB burden (92 per 100,000 person-year(PY)) [7] .
Methods

Study patients
Overall, between December, 2004, and September, 2012, 1279 consecutive patients with IMIDs were screened at the Asan Medical Center, a 2700-bed referral hospital in Seoul, South Korea, for LTBI before starting treatment with TNF antagonists. Of these cases, 132 patients (10.3%) had a previous history of anti-TB treatment irrespective of the confirmation of TB diagnosis. During screening, three of these patients (2.3%) were diagnosed with active pulmonary TB and were therefore excluded from further analysis. Of the remaining 129 patients, 101 were started on a TNF antagonist therapy. The decision not to use TNF-a inhibitors in 28 patients was based on their IMID status, not on their TB infection status. The clinical outcomes in these 101 patients were retrospectively analyzed in December 2012. RA and AS were diagnosed using previously proposed criteria [8, 9] . CD and UC were diagnosed based on a composite of endoscopic, radiographic, and pathologic findings as described previously [10] .
Our current study protocol was approved by the Institutional Review Board of the Asan Medical Center, which waived the requirement for informed consent due to the retrospective nature of the analysis. However, some of our study subjects who had been evaluated in a previous study provided informed consent for TST and IGRA tests [1, 5] .
LTBI screening methods
The medical histories assessed at screening included current symptoms, a prior history of treatment for TB, the presence of underlying disease, and recent contact with individuals with active pulmonary TB. CXR, TST, and IGRA were performed on the same day that the patient's history was taken. Patients with CXR abnormalities suggestive of previous TB sequelae, such as fibrostreaky lesions or multiple calcified nodules in the upper lobe, were assessed using a sputum acid-fast bacilli (AFB) smear/culture to rule out active TB. In addition, present and former CXR results were compared to determine the presence of newly developed lesions.
Each TST was performed via the intradermal injection of 2 tuberculin units of purified protein derivative (PPD) RT23 (Statens Serum Institute, Copenhagen, Denmark) into the forearm using the Mantoux technique [11] . Reactions were evaluated 48e72 h later, with positive results defined as indurations of !10 mm in the transverse diameter according to the Korean Guideline for Tuberculosis [12] . At our institution, both kinds of IGRA were used sequentially for LTBI screening during the study period. T-SPOT Ò .TB (T-SPOT; Oxford Immunotec, Abingdon, UK) tests were performed up to July 2011 (n Z 72) and QuantiFERON Ò TB-Gold In Tube (QFT-GIT; Cellestis Ltd, Carnegie, Australia) tests have been used since then (n Z 29). A T-SPOT assay result was defined as positive when the number of spots in the TB-antigen well minus the number of spots in the negative control well was !6. The QFT-GIT assay is performed in two stages, in accordance with the manufacturer's instructions. One milliliter aliquots of blood are drawn directly into three evacuated blood collection tubes, one containing heparin alone (negative control), one containing T cell mitogens (positive control), and one containing M. tuberculosis-specific antigens including early secreted antigenic target 6 and culture filtrate protein 10 (TB-antigen tube). Following overnight incubation, 200 mL of plasma is removed from each well and the concentration of interferon-gamma (IFN-g) is determined by ELISA. A positive response is defined as an antigennil IFN-g concentration of !0.35 IU/mL.
Diagnosis and treatment of LTBI
From July 2004 to March 2008, a positive LTBI was defined as a TST induration of !10 mm or, if the induration was <10 mm but !5 mm, as a positive T-SPOT test [1] . Beginning in April 2008, a positive LTBI was defined as a TST induration of !10 mm or by a positive T-SPOT or QTF-GIT result [5] .
In our study subjects, the decision to initiate LTBI treatment was based on the adequacy of previous anti-TB treatments and the history of recent contact with patients with infectious TB, irrespective of the LTBI test results. When LTBI treatment was indicated, treatment with TNF antagonists was initiated at least 3 weeks later [12] . Guidelines of the Korean Centers for Disease Control and Prevention recommend the use of isoniazid (INH) for 9 months, rifampicin (RFP) for 4 months, or both INH and RFP for 3 months [5] . The selection of these regimens is at the discretion of each attending physician.
Follow-up
TNF antagonists and LTBI treatments were prescribed independently by attending physicians and pulmonologists, respectively. Regardless of their LTBI status, all patients were scheduled for a follow-up with a pulmonologist for at least 6 months after completion of TNF antagonist treatment. CXR was usually performed 3 and 9 months after the initiation of TNF antagonists and every 12 months thereafter. Patients were instructed to visit their pulmonologists if new symptoms or signs suggestive of TB developed.
Statistical analysis
Continuous variables were compared using Student's ttests, and categorical variables using the c 2 or Fisher's exact test, as appropriate. All tests of significance were two sided; p values <0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 12.0; SPSS Inc., Chicago, IL).
Results
Characteristics of the study subjects
The mean age of the 101 subjects in the current study cohort was 40.4 AE 16.0 years and 51 cases (50.5%) were male. IMIDs included CD in 55 (54.5%), RA in 27 (26.7%), and AS in 13 (12.9%) patients. Of these 101 cases, 53 (52.5%) had a history of pulmonary TB, 47 (46.5%) had intestinal TB, and one (1.0%) had cervical TB lymphadenitis. All 30 patients (29.7%) who had been tested for human immunodeficiency virus (HIV) were negative. These clinical characteristics are presented in Table 1 . Patients with a previous history of anti-TB treatment for intestinal TB were significantly younger and had more normal CXR findings than the remaining patients. Most anti-TB treatments were administered to differentiate between intestinal TB and inflammatory bowel diseases in patients with history of intestinal TB.
Diagnosis and treatment of LTBI
Overall, TST results were positive in 22 (21.8%) patients and IGRA in 45 (44.6%). Patients with a history of intestinal TB had significantly lower rates of positivity on both tests (Table 1 ). Based on positive results from the TST and/or IGRA tests, 49 (48.5%) patients were determined to have LTBI. Of the 101 patients in our total cohort, 11 (10.9%) were started on LTBI treatment. This was due to inadequate previous anti-TB treatment in five cases, uncertainty about previous anti-TB treatment in another five cases, and recent contact with a patient with infectious pulmonary TB in one case. Five patients were treated with RIF, four with INH/RIF, and two with INH alone. All 11 patients completed this LTBI treatment. Table 2 lists the clinical characteristics of the 101 study subjects in accordance with whether they received treatment for LTBI. CXR revealed lesions suggestive of previous TB sequalae in 33 (32.7%) of 101 patients. However, none of these 33 patients developed active TB. Of the 11 patients in our cohort treated for LTBI, CXR results showed previous TB sequalae lesions in 6 cases.
Development of TB after initiation of anti-TNF agents
The median follow-up duration after the initiation of TNF antagonist treatments of all 101 study subjects and the 90 patients who were not treated for LTBI was 31.5 months (interquartile range 〔IQR〕 15.3e47.8 months) and 35.2 months (〔IQR〕 17.7e50.0 months), respectively. The median duration of treatment with TNF antagonists in all 101 patients in the study cohort, the 11 patients treated for LTBI, and the 90 patients not treated for LTBI was 22.5 months (〔IQR〕9.1e46.7 months), 14.3 months (〔IQR〕 9.1e46.7 months), and 24.7 months (〔IQR〕10.5e46.6 months), respectively.
One patient with AS among the 90 patients who had not been treated for LTBI developed active pulmonary TB. This patient had been treated with etanercept and developed active pulmonary TB 6 years after TNF antagonist treatment had been initiated. Overall, only one case of TB developed in our study cohort during 297 PY of follow-up, equaling a TB incidence rate of 336 per 100,000 PY.
Discussion
Although some patients in TB endemic areas who are candidates for TNF antagonist treatment have a previous history of TB, little is currently known about the methods of selecting patients who require LTBI treatment and the incidence of TB in these patients. To our knowledge, our present study was the first to investigate the incidence of TB in patients with a previous history of anti-TB treatment during anti-TNF therapy. When compared with the incidence rate of TB in patients with IMIDs who have been treated using TNF blockers with two different LTBIdiagnosing strategies at our institution (813 per 100,000 PY [1] and 382 per 100,000 PY [5] ), the most important finding of this study was that TNF antagonists can be administered to patients who had a previous history of TB with acceptable incidence of TB (336 per 100,000 PY), after receiving appropriate LTBI treatment based on the adequacy of previous treatment and recent contact with patients with active TB in TB-prevalent countries.
Although TST screening for LTBI in patients with a history of anti-TB treatment is meaningless for selecting candidates for LTBI treatment, TST and/or IGRA are used to screen for LTBI in patients who are candidates for anti-TNF therapy. Both tests were performed routinely for some of our current patients, whereas in other cases they have been performed as a part of a prospective study [1, 5] . However, the decision to treat LTBI or not was not dependent on the results of these LTBI tests but on the patient's medical history, CXR findings, and recent contact history with individuals with infectious TB. Following this strategy, anti-TNF agents can be cautiously used in patients with a previous history of anti-TB treatment. Within a median follow-up of 31.5 months, only one patient (1.0%) in our study cohort developed TB. Moreover, the occurrence of TB in this patient 6 years after the initiation of TNF antagonist treatments suggests that it may have been due to re-infection and not to a reactivation of latent foci [13] . This patient was not indicated for LTBI treatment, since the previous anti-TB treatment had been adequate and there was no history of recent contact with patients with infectious TB.
Although all of our study subjects reported a previous history of TB, it is unlikely that all had true active TB. Intestinal TB was not confirmed bacteriologically in any of the patients with this indication but was diagnosed based on clinical findings alone, such as a colonoscopic appearance. Hence, most of these patients were treated with anti-TB drugs to differentiate between intestinal TB and IBD, as suggested by their low rates of positivity on both TST and IGRA. However, since positivity on LTBI tests has been found to vary according to underlying diseases in patients without a previous history of TB [14] , the different rates of positivity on these tests may have been due to differences in underlying diseases. We also found that patients with CD in our present cohort had significantly lower rates of positivity on TST (4.9% vs. 41.2%, p < 0.001) and QTF-GIT (28.8% vs. 63.9%, p < 0.001) tests than patients with AS (data not shown).
Of the 54 patients in our study cohort with a history of previous TB other than intestinal TB, 53 cases had pulmonary TB, with 31 (58.5%) patients having CXR findings suggestive of prior TB infection sequelae. However, only 37% and 67% were positive on TST and QFT-GIT tests, respectively, which may have been due to their high rate of treatment with antiinflammatory drugs, including steroids and/or disease modifying anti-rheumatic drugs. This possibility is supported by the even higher TST and QFT-GIT positivity rates, 54.6% and 77.7%, respectively, that were reported among healthy subjects with a CXR showing of old healed TB lesions [15] . However, only 58.5% of our current patients had CXR findings suggestive of TB, which may be responsible for the lower rates of LTBI positivity we observed.
Previous studies have reported that the risk of TB is higher in patients treated with an anti-TNF monoclonal antibody (infliximab or adalimumab) than in patients treated with a soluble TNF receptor (etanercept). This is probably because these treatments act differently on membrane-bound TNF and thereby have different effects on effector T cell and Treg cells [16] . The patient in our present study who developed active pulmonary TB had been treated with etanercept but as only one of our current cases developed TB, it was not possible to evaluate whether any of the anti-TNF agents used in our study cohort significantly affected the incidence of TB.
Our present study had several noteworthy limitations. First, all of our patients were from a single referral center and we analyzed a relatively small number of cases. Further studies with larger sample sizes are thus needed to confirm our findings. Second, we obtained the histories of TB exposure from patient interviews only. Third, two different LTBI-diagnosing strategies were used sequentially. However, as already mentioned, LTBI test results were not used to select the candidates for LTBI treatment. Finally, many of our patient subjects with a history of anti-TB treatment for intestinal TB may not have actually had TB. Even after excluding these cases, however, the number of remaining patients with a previous history of TB (n Z 54) is still one of the largest studied cohorts of patients with TB who received anti-TNF treatments [5, 17] .
In conclusion, the results presented here suggest that patients with IMIDs and a previous history of TB can be treated with TNF antagonists with acceptable incidence of TB, after receiving appropriate LTBI treatment if this choice of therapy is based on the adequacy of previous TB treatments and a knowledge of recent contact with active TB in TB-prevalent countries.
